Investing.com - Aslan Pharma ADR reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Aslan Pharma ADR announced earnings per share of -0.15 on revenue of 0.00. Analysts polled by Investing.com anticipated EPS of -0.0967 on revenue of 0.00.
Aslan Pharma ADR shares are up 67.21% from the beginning of the year and are trading at 3.060 , down-from-52-week-high.They are outperforming the Nasdaq which is up 8.38% from the start of the year.
Aslan Pharma ADR shares gained 2.34% in intra-day trade the report.
Aslan Pharma ADR follows other major Healthcare sector earnings this month
Aslan Pharma ADR's report follows an earnings beat by J&J on Tuesday, who reported EPS of 2.59 on revenue of 22.32B, compared to forecasts EPS of 2.33 on revenue of 22.01B.
Abbott Labs had beat expectations on Tuesday with first quarter EPS of 1.32 on revenue of 10.46B, compared to forecast for EPS of 1.27 on revenue of 10.69B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar